Men’s Health, Women’s Health and Genitourinary
Overview of the global testosterone replacement therapy market
Technavio’s market research analyst predicts that the global testosterone replacement therapy market will generate revenues of over USD 2 billion by the end of the estimated period. A key driver influencing the growth of this market is the increased prevalence of chronic diseases around the world. Low testosterone levels can cause chronic problems like diabetes, heart disease, and can even exacerbate conditions like rheumatoid arthritis. Since these chronic conditions lead to disorders in the hypothalamic-pituitary-gonadal axis, the demand for testosterone replacement therapy will increase significantly over the next few years. This recent increase in the number of individuals with low testosterone levels will have a positive impact on the market’s growth potential during the forecast period.
In this industry report, the analysts estimate factors like the availability selective androgen receptor modulators (SARMs) to spur market growth during the forecast period. Testosterone therapies are available in injectable form or delivery through the skin. The development and free availability of SARMs are considered a better treatment option for people with androgen deficiencies. Taken orally, SARMS elicit the desired response by targeting androgen receptors. The availability of effective drug delivery systems like SARMS will propel market growth until the end of 2020.
Segmentation by dosage form and analysis of the testosterone replacement therapy market
In 2015, the gels segment accounted for the largest share of the testosterone replacement therapy market with approximately 66% market share. Gels are available in a semi-solid form and contain an active ingredient, which can be applied locally for
Overview of the endometriosis drugs market
According to the market research analysts at Technavio, the global endometriosis drugs market is expected to witness steady growth and will post a moderate CAGR of more than 2% over the forecast period. Oral contraceptive pills (OCPs) are essentially hormonal pills containing estrogen and progestin hormones similar to those produced by the ovaries. Besides contraceptives, these pills are also found to be effective in treating endometriosis. Although they do not cure endometriosis, they are helpful in alleviating pain and preventing the condition from getting worse. Moreover, these medications also lower the chances of getting endometrial and ovarian cancer, ovarian cysts, certain breast lumps, and also protects an individual from osteoporosis. These factors will lead to their augmented adoption of OCPs, which will positively impact the endometriosis drugs market in the coming years.
One of the significant trends propelling this market’s growth prospects is the increasing focus and adoption of intrauterine devices (IUDs). Presently, the treatment of endometriosis includes the use of GnRH agonists and oral contraceptives. However, most of these therapies are associated with several adverse effects due to hormonal changes in the body along with the early recurrence of the disease. Therefore, the growing need for the replacement of these conventional therapies will lead to the development of IUDs releasing birth control hormones.
Outlook of the postmenopausal osteoporosis drugs market
Technavio’s market research analyst predicts the global postmenopausal osteoporosis drugs market to grow steadily at a CAGR of more than 4% over the forecast period. With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years. The postmenopausal osteoporosis drugs market is characterized by the presence of promising late-stage molecules that are being developed by the major and upcoming players in this market. Some of the late-stage pipeline molecules that are envisaged to be launched during the forecast period are Tarsa Therapeutics’ TBRIA, romosozumab, Merck’ odanacatib (Phase III), and Radius Health’s abaloparatide (Phase III).
In this industry research report, the analysts have estimated factors such as the emergence of combination therapies to contribute to this market’s growth in the next four years. Anabolic and antiresorptive agents can significantly enhance bone density and strength as a combination therapy than as monotherapy. Clinical trials have been performed evaluating the effect of PTH1-34 or PTH1-84 in combination with antiresorptive drugs, including raloxifene, alendronate, and risedronate. Moreover, it has been observed that combining antiresorptive drugs with PTH or teriparatide has been successful in providing greater bone mineral density. For instance, Pfizer's Duavee is a combination of conjugated estrogens and bazedoxifene used in the treatment of postmenopausal osteoporosis with few side effects.
Segmentation by line of therapy and analysis of the postmenopausal osteoporosis drugs market
- First line of therapy
- Second line of therapy
During 2015, the first line of therapy segment dominated the market and accounted for more than 64% of the market
Outlook of the postmenopausal vaginal atrophy (PVA) market
Extensive research carried out by the analysts at Technavio has shown that the global postmenopausal vaginal atrophy (PVA) market will grow at an impressive CAGR of more than 7% over the forecast period.The presence of favorable healthcare reforms in the US is one of the key factors driving this market in the coming years. The Affordable Care Act has increased the number of insured women and has been a driving factor in the treatment-seeking behavior of people with this condition. Moreover, this law provides Americans with better health security by putting in place comprehensive health insurance reforms that not only have lower health care costs but also expands the coverage. Therefore, the introduction of beneficial healthcare plans in the US will prompt more women to with PVA to seek treatment, thereby aiding in the growth of this market over the forecast period.
In this industry research report, the analysts have estimated that the paradigm shift to non-estrogenic therapies is one of the critical trends driving this market’s growth. Non-estrogenic therapies in PVA treatment are a paradigm shift from systemic estrogen treatments such as creams, patches, and gels. Moreover, the launch of late-stage pipeline products expected to shift the attention from vaginal creams and OTC classes toward vaginal tablets and oral therapies. Therefore, the growing adoption of non-estrogenic therapies will propel the growth of this market segment during the forecast period.
Segmentation by drug class and analysis of the PVA market
- Topical estrogen
- Systemic estrogen
The topical estrogen segment dominated the market and accounted for almost 60% of the market share. Topical estrogen supplies include vaginal creams, vaginal tablet, and vaginal ring to drive this market
About stem cell
Stem cells are the building blocks of the human body. They originate in the earliest stage of human development and can be found in the various stages of growth from birth till adulthood. When these undifferentiated biological cells divide, they can differentiate into specialized cells. A stem cell bank is a facility that stores stem cells for future use. Stem cell banking, one of the most promising markets in the field of life sciences, is the process of preserving stem cells at temperatures much below the freezing point. This technique is termed as cryopreservation. These cells can be used in the treatment of Parkinson's disease, diabetes, cancer, heart diseases, and others. Traditionally, the stem cells can be classified into three types based on the origin: embryonic stem cells, adult stem cells, and germinal stem cells.
Technavio's analysts forecast the global stem cell banking market to grow at a CAGR of 15.13% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global stem cell banking market for the period 2014-2019. To calculate the market size, the report considers the revenue generated by the leading stem cell banks. The report also considers the revenue generated by various segments of stem cell banks to arrive at the final market size which includes:
Technavio's report, Global Stem Cell Banking Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Obesity is a complex multifactorial disorder characterized by the excessive accumulation and storage of fat in the body. In the recent years, this chronic illness is being considered as a global epidemic owing to its strikingly increasing incidence rates, especially in the in low and middle-income countries. Sedentary lifestyles and lack of physical activity coupled with consumption of high-calorie diet are considered to be the most preventable causes of obesity. Being either overweight or obese is considered as a risk factor for the development of multiple chronic diseases including cardiovascular disorders such as coronary heart disease, dyslipidemia, hypertension; metabolic disorders such as diabetes; and cancers to highlight a few. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.
Technavio's analysts forecast the anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the anti-obesity drugs market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the currently approved patented drugs, generics, OTC products, and the available generics that are used for the treatment of obesity.
Technavio's report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the
key vendors operating in this market.
• Arena Pharmaceuticals
• F. Hoffmann-La Roche
• Novo Nordisk
In the rapidly growing pharmaceutical market, drugs for sex-specific disorders and diseases constitute unique therapeutic segments. An in-depth understanding of the etiologies and pathophysiologies of both female and male diseases is increasing the scope for pharmaceutical research and development of best-in-class drugs.
Additionally, the standard of care for genitourinary disorders has improved over the years. For instance, treatments for several sexual dysfunctions and urinary system diseases have evolved significantly in the recent past.
Innovations, advanced pharmaceutical marketing, and the development and commercialization of drugs involved in this therapeutic segment are predicted to expand the market’s size.